Celltrion to unveil obesity drug milestone before year-end

Celltrion said Wednesday it expects a series of key research and clinical milestones over the next year.

Preclinical data for its next-generation obesity treatment is due later this year, and initial clinical results from several oncology drug candidates are scheduled for the first half of next year.

According to Celltrion, it plans to disclose preclinical findings for its world's first quad-agonist obesity drug candidate CT-G32 in November and submit an investigational new drug, or IND, applica ...